"The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
Simponi works by blocking tumor necrosis factor (TNF), which plays an important"...
- Patient Information:
Details with Side Effects
The most serious adverse reactions seen in CANASA clinical trials or with other products that contain or are metabolized to mesalamine are:
- Renal impairment, including renal failure [See WARNINGS AND PRECAUTIONS]
- Mesalamine-induced acute intolerance syndrome [See WARNINGS AND PRECAUTIONS]
- Hypersensitivity reactions [See WARNINGS AND PRECAUTIONS]
- Hepatic impairment, including hepatic failure [See WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- The most frequent adverse reactions observed in the double-blind, placebo-controlled trials are summarized in the Table 1 below.
Table 1: ADVERSE REACTIONS OCCURRING IN MORE THAN 1%
OF MESALAMINE SUPPOSITORY TREATED PATIENTS (COMPARISON TO PLACEBO)
|Symptom||Mesalamine (n = 177)||Placebo (n = 84)|
In a multicenter, open-label, randomized, parallel group study comparing the CANASA 1000 mg suppository administered nightly to that of the CANASA 500 mg suppository twice daily, the two treatment groups had similar adverse event profiles. The most frequent AEs were headache (14.4%), flatulence (5.2%), abdominal pain (5.2%), diarrhea (3.1%), and nausea (3.1%). Three (3) patients had to discontinue medication because of an adverse reaction; one of these adverse reactions (headache) was deemed possibly related to study medication.
In addition to the adverse reactions reported above in clinical trials involving CANASA, the adverse reactions listed below have been identified during post-approval use of CANASA and other mesalamine-containing products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Body as a Whole: drug fever, fatigue, lupus-like syndrome, medication residue
- Cardiac Disorders: myocarditis, pericarditis, pericardial effusion
- Eye disorders: eye swelling
- Gastrointestinal Disorders: abdominal cramps, abdominal distension, anal pruritus, anorectal discomfort, constipation, feces discolored, flatulence, frequent bowel movements, gastrointestinal bleeding, mucus stools, nausea, painful defecation, pancreatitis, proctalgia, rectal discharge, rectal tenesmus, stomach discomfort, vomiting
- Hepatic Disorders: cholestatic jaundice, hepatitis, jaundice, Kawasaki-like syndrome including changes in liver enzymes, liver necrosis, liver failure
- Hematologic Disorders: agranulocytosis, aplastic anemia, thrombocytopenia
- Neurological/Psychiatric Disorders: Guillain-Barre syndrome, peripheral neuropathy, transverse myelitis
- Renal Disorders: interstitial nephritis
- Respiratory, Thoracic and Mediastinal Disorders: hypersensitivity pneumonitis (including allergic alveolitis, eosinophilic pneumonitis, interstitial pneumonitis)
- Skin and subcutaneous tissue Disorder: alopecia, erythema, erythema nodosum, pruritus, psoriasis, pyoderma gangrenosum, urticaria
- Urogenital: reversible oligospermia
Read the Canasa (mesalamine) Side Effects Center for a complete guide to possible side effects
No investigations of interaction between CANASA and other drugs have been performed. However, the following interactions between mesalamine medications and other drugs have been reported.
Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs
The concurrent use of mesalamine with known nephrotoxic agents, including nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of renal reactions.
Azathioprine or 6-mercaptopurine
The concurrent use of mesalamine with azathioprine or 6mercaptopurine may increase the risk for blood disorders.
Read the Canasa Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 2/26/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Canasa Information
Canasa - User Reviews
Canasa User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.